PROCEPT BioRobotics Corporation (PRCT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. But what's the best way to find the right combination ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 16th: Core ...

MEMPHIS, Tenn. (AP) — MEMPHIS, Tenn. (AP) — First Horizon National Corp. (FHN) on Thursday reported fourth-quarter profit of $165 million. The bank, based in Memphis, Tennessee, said it had earnings ...

UnitedHealth expects full-year earnings in the range of $29.50 to $30 per share, with revenue in the range of $450 billion to $455 billion. This story was generated by Automated Insights ( ...

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $2.16 per share. The chip company posted revenue of ...